Imperial College London

A phase 3 randomized controlled trial of 820 adults found that VER-01, a standardized full-spectrum cannabis extract, reduced chronic low back pain by 1.9 points versus 1.4 for placebo on the numeric rating scale.

Vapendavir demonstrated beneficial effects in treating rhinovirus infections in COPD patients, improving patient-reported outcomes, reducing viral load, and maintaining lung function compared to placebo in a 40-participant challenge study.

A randomized controlled trial of 360 children aged 5-15 found that a budesonide-formoterol combination inhaler reduced asthma attacks by 45% compared to standard salbutamol treatment.

Faeth Therapeutics announced positive Phase 2 data from the DICE trial showing sapanisertib can improve ovarian cancer treatment when combined with paclitaxel.

MIT researchers used generative AI to design two novel antibiotics capable of killing drug-resistant gonorrhea and MRSA in laboratory and animal tests.

Imperial College London's REACT programme, which built a 2.5 million participant cohort during COVID-19, will partner with the Dementia Trials Accelerator to address chronic recruitment challenges in UK dementia clinical trials.

The TOPSPIN trial, led by AIIMS Delhi, found that three commonly used two-drug combination pills for hypertension showed equal effectiveness in reducing blood pressure among South Asian patients, with all combinations achieving approximately 14/8 mmHg reduction in 24-hour ambulatory measurements.

A network meta-analysis of nine phase III trials involving 6,425 patients found that atezolizumab plus bevacizumab offered the most favorable balance between survival benefit and quality-of-life preservation in advanced hepatocellular carcinoma.

Modus Therapeutics announced a fully secured rights issue of SEK 28.3 million to finance continued clinical development of sevuparin, a drug candidate for chronic kidney disease with anemia.

MAIA Biotechnology appointed two prominent hepatocellular carcinoma specialists, Dr. Claudia Fulgenzi and Dr. David J. Pinato, to its Scientific Advisory Board to guide upcoming clinical trials.